Low-Density Lipoprotein Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk)

Circulation

Volumn 137, Issue 4, 2018, Pages 338-350

  Bonaca, Marc P ^a   Nault, Patrice ^b   Giugliano, Robert P ^a   Keech, Anthony C ^c   Pineda, Armando Lira ^d   Kanevsky, Estella ^a   Kuder, Julia ^a   Murphy, Sabina A ^a   Jukema, J Wouter ^e   Lewis, Basil S ^f   Tokgozoglu, Lale ^g   Somaratne, Ransi ^d   Sever, Peter S ^h   Pedersen, Terje R ⁱ   Sabatine, Marc S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF SYDNEY   (Australia)

^d AMGEN INC   (United States)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^g HACETTEPE UNIVERSITY   (Turkey)

^h NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

ⁱ UNIVERSITY OF OSLO   (Norway)

Author keywords

amputation; atherosclerosis; cholesterol, LDL; evolocumab; intermittent claudication; PCSK9 protein, human; peripheral arterial disease

Indexed keywords

EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROPROTEIN CONVERTASE 9; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE INHIBITOR;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE; FOLLOW UP; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INTERMITTENT CLAUDICATION; LEG AMPUTATION; LEG ISCHEMIA; LEG REVASCULARIZATION; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AMPUTATION; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DYSLIPIDEMIA; LIMB SALVAGE; METABOLISM; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TIME FACTOR;

AGED; AMPUTATION; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; BIOMARKERS; CHOLESTEROL, LDL; DOWN-REGULATION; DYSLIPIDEMIAS; FEMALE; HUMANS; LIMB SALVAGE; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PROPROTEIN CONVERTASE 9; RISK FACTORS; SERINE PROTEINASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85048211174     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.032235     Document Type: Article

References (38)

1. Suárez C, Zeymer U, Limbourg T, Baumgartner I, Cacoub P, Poldermans D, Röther J, Bhatt DL, Steg PG, REACH Registry Investigators Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry. Vasc Med 2010 15 259 265. doi: 10.1177/1358863X10373299.
2. Criqui MH, Aboyans V, Epidemiology of peripheral artery disease. Circ Res 2015 116 1509 1526. doi: 10.1161/CIRCRESAHA.116.303849.
3. Bonaca MP, Bhatt DL, Storey RF, Steg PG, Cohen M, Kuder J, Goodrich E, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Dalby A, Špinar J, Aylward P, Corbalán R, Abola MTB, Jensen EC, Held P, Braunwald E, Sabatine MS, Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol 2016 67 2719 2728. doi: 10.1016/j.jacc.2016.03.524.
4. Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, Rother J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I, 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS) [published online ahead of print August 26, 2017]. Eur Heart J. doi: 10.1093/eurheartj/ehx095. https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehx095
5. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME, 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017 135 e726 e779. doi: 10.1161/CIR.0000000000000471.
6. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Goto S, Ohman EM, Elbez Y, Sritara P, Baumgartner I, Banerjee S, Creager MA, Bhatt DL, REACH Registry Investigators Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 2014 35 2864 2872. doi: 10.1093/eurheartj/ehu080.
7. Jones WS, Baumgartner I, Hiatt WR, Heizer G, Conte MS, White CJ, Berger JS, Held P, Katona BG, Mahaffey KW, Norgren L, Blomster J, Millegård M, Reist C, Patel MR, Fowkes FG, International Steering Committee and Investigators of the EUCLID Trial Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation 2017 135 241 250. doi: 10.1161/CIRCULATIONAHA.116.025880.
8. Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, Lamp JM, Murphy SA, Braunwald E, Morrow DA, Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation 2013 127 1522 1529, 1529e1. doi: 10.1161/CIRCULATIONAHA.112.000679.
9. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC, Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007 4 CD000123
10. Aronow WS, Nayak D, Woodworth S, Ahn C, Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003 92 711 712
11. Mohler ER III, Hiatt WR, Creager MA, Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003 108 1481 1486. doi: 10.1161/01.CIR.0000090686.57897.F5.
12. Spring S, Simon R, van der Loo B, Kovacevic T, Brockes C, Rousson V, Amann-Vesti B, Koppensteiner R, High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial. Thromb Haemost 2008 99 182 189. doi: 10.1160/TH07-04-0265.
13. Schanzer A, Hevelone N, Owens CD, Beckman JA, Belkin M, Conte MS, Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg 2008 47 774 781. doi: 10.1016/j.jvs.2007.11.056.
14. Anand S, COMPASS Investigators COMPASS PAD-Cardiovascular OutcoMes for People using Anticoagulation StrategieS trial: Results in Patients with Peripheral Artery Disease. European Society of Cardiology Hotline 2017. http://congress365.escardio.org/Presentation/162172#.WgCm1o9SzmE. Accessed November 7, 2017
15. Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegård M, Reist C, Patel MR, EUCLID Trial Steering Committee and Investigators Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017 376 32 40. doi: 10.1056/NEJMoa1611688.
16. Sabatine MS, Giugliano RP, Keech A, Honarpour N, Wang H, Liu T, Wasserman SM, Scott R, Sever PS, Pedersen TR, Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am Heart J 2016 173 94 101. doi: 10.1016/j.ahj.2015.11.015.
17. Bonaca MP, Gutierrez JA, Creager MA, Scirica BM, Olin J, Murphy SA, Braunwald E, Morrow DA, Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50). Circulation 2016 133 997 1005. doi: 10.1161/CIRCULATIONAHA.115.019355.
18. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S, COMPASS Investigators Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017 377 1319 1330. doi: 10.1056/NEJMoa1709118.
19. Sabatine MS, Giugliano RP, Pedersen TR, Evolocumab in patients with cardiovascular disease. N Engl J Med 2017 377 787 788. doi: 10.1056/NEJMc1708587.
20. Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS, FOURIER Investigators Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial [published online ahead of print August 25, 2017]. Lancet. doi: 10.1016/S0140-6736(17)32290-0. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32290-0/fulltext
21. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA, CHARISMA Investigators Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009 30 192 201. doi: 10.1093/eurheartj/ehn534.
22. Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, Gibson CM, Kleiman NS, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC Jr, Pollack CV Jr, Gibler WB, Ohman EM, Roe MT, CRUSADE Investigators Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J 2009 30 1195 1202
23. Franzone A, Piccolo R, Gargiulo G, Ariotti S, Marino M, Santucci A, Baldo A, Magnani G, Moschovitis A, Windecker S, Valgimigli M, Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: a subgroup analysis of the PRODIGY Randomized Clinical Trial. JAMA Cardiol 2016 7 796 803
24. Chen DC, Singh GD, Armstrong EJ, Waldo SW, Laird JR, Amsterdam EA, Long-term comparative outcomes of patients with peripheral artery disease with and without concomitant coronary artery disease. Am J Cardiol 2017 119 1146 1152. doi: 10.1016/j.amjcard.2016.12.023.
25. Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, Sussex B, Liu L, Guzman R, Cina C, Crowell R, Keltai M, Gosselin G, Warfarin Antiplatelet Vascular Evaluation Trial Investigators Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007 357 217 227
26. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004 363 757 767. doi: 10.1016/S0140-6736(04)15690-0.
27. Heart Protection Study Collaborative Group Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007 45 645 654. discussion 653-654
28. Foley TR, Singh GD, Kokkinidis DG, Choy HK, Pham T, Amsterdam EA, Rutledge JC, Waldo SW, Armstrong EJ, Laird JR, High-intensity statin therapy is associated with improved survival in patients with peripheral artery disease. J Am Heart Assoc 2017 6. doi: 10.1161/JAHA.117.005699. e005699
29. Stavroulakis K, Borowski M, Torsello G, Bisdas T, CRITISCH collaborators Association between statin therapy and amputation-free survival in patients with critical limb ischemia in the CRITISCH registry. J Vasc Surg 2017 66 1534 1542. doi: 10.1016/j.jvs.2017.05.115.
30. Westin GG, Armstrong EJ, Bang H, Yeo KK, Anderson D, Dawson DL, Pevec WC, Amsterdam EA, Laird JR, Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol 2014 63 682 690. doi: 10.1016/j.jacc.2013.09.073.
31. Giri J, McDermott MM, Greenland P, Guralnik JM, Criqui MH, Liu K, Ferrucci L, Green D, Schneider JR, Tian L, Statin use and functional decline in patients with and without peripheral arterial disease. J Am Coll Cardiol 2006 47 998 1004. doi: 10.1016/j.jacc.2005.10.052.
32. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, Laakso M, Baker JR, Keech AC, FIELD study investigators Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009 373 1780 1788. doi: 10.1016/S0140-6736(09)60698-X.
33. Dosluoglu HH, Davari-Farid S, Pourafkari L, Harris LM, Nader ND, Statin use is associated with improved overall survival without affecting patency and limb salvage rates following open or endovascular revascularization. Vasc Med 2014 19 86 93. doi: 10.1177/1358863X14528271.
34. Feringa HH, Karagiannis SE, van Waning VH, Boersma E, Schouten O, Bax JJ, Poldermans D, The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg 2007 45 936 943. doi: 10.1016/j.jvs.2007.01.024.
35. Aiello FA, Khan AA, Meltzer AJ, Gallagher KA, McKinsey JF, Schneider DB, Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia. J Vasc Surg 2012 55 371 379. discussion 380. doi: 10.1016/j.jvs.2011.08.044.
36. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R, Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016 388 2532 2561. doi: 10.1016/S0140-6736(16)31357-5.
37. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015 372 1500 1509. doi: 10.1056/NEJMoa1500858.
38. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 1383 1389